ArticleCureus2026
Biventricular Heart Failure With Reduced Ejection Fraction in a Young Male: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 33-year-old male with a past medical history of nonischemic cardiomyopathy with a reduced ejection fraction (HFrEF) and hypertension presented with worsening dyspnea and chest pain. This had started over the past three days but had not improved, prompting him to come to the emergency department. His vitals were unremarkable on presentation. Initial evaluation due to his history of HFrEF was obtaining an echocardiogram, which revealed an ejection fraction of 15%-20%, similar to the previous echocardiogram. He underwent cardiac MRI later, which showed an ejection fraction of 6% for the left ventricle and 17% for the right ventricle. Multidisciplinary teams optimized guideline-directed medical therapy (GDMT) during this hospitalization, including uptitration of sacubitril-valsartan, metoprolol succinate, spironolactone, and initiation of empagliflozin and digoxin. Right heart catheterization guided management, and a wearable defibrillator bridged to future implantable cardioverter-defibrillator placement. Severe obstructive sleep apnea was diagnosed and treated with continuous positive airway pressure (CPAP). The patient was discharged home in stable condition after one week with an optimized regimen, with advanced therapy evaluation including transplant workup. This case highlights GDMT optimization in young patients with advanced HFrEF, potential for recovery, and bridging strategies, addressing a complex and tenuous disease status in an increasingly more common patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.